Steffen Falgreen

500 total citations
19 papers, 255 citations indexed

About

Steffen Falgreen is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Steffen Falgreen has authored 19 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Steffen Falgreen's work include Lymphoma Diagnosis and Treatment (9 papers), Cancer Genomics and Diagnostics (4 papers) and Gene expression and cancer classification (4 papers). Steffen Falgreen is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Cancer Genomics and Diagnostics (4 papers) and Gene expression and cancer classification (4 papers). Steffen Falgreen collaborates with scholars based in Denmark, United States and United Kingdom. Steffen Falgreen's co-authors include Karen Dybkær, Hans Erik Johnsen, Julie Støve Bødker, Martin Bøgsted, Alexander Schmitz, Maria Bach Laursen, Malene Krag Kjeldsen, Anders Ellern Bilgrau, Mette Nyegaard and Tarec Christoffer El‐Galaly and has published in prestigious journals such as Blood, PLoS ONE and BMC Bioinformatics.

In The Last Decade

Steffen Falgreen

19 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steffen Falgreen Denmark 10 135 94 87 67 60 19 255
Jeffrey C. Xing United States 9 177 1.3× 102 1.1× 58 0.7× 78 1.2× 75 1.3× 14 350
Stéphanie Sungalee Switzerland 7 286 2.1× 89 0.9× 93 1.1× 89 1.3× 58 1.0× 7 413
Rina Kurisu Japan 7 102 0.8× 26 0.3× 40 0.5× 59 0.9× 132 2.2× 9 335
Luke B. Fletcher United States 8 168 1.2× 42 0.4× 51 0.6× 64 1.0× 61 1.0× 16 328
Elena Battistello Switzerland 6 234 1.7× 51 0.5× 115 1.3× 98 1.5× 56 0.9× 7 358
Jens Wuerthner United States 11 108 0.8× 124 1.3× 31 0.4× 245 3.7× 52 0.9× 24 335
Romina Royo Spain 8 386 2.9× 81 0.9× 159 1.8× 49 0.7× 65 1.1× 15 522
Martina Fröhlich Germany 7 162 1.2× 41 0.4× 103 1.2× 73 1.1× 18 0.3× 17 315
Elizabeth Carideo United States 5 150 1.1× 138 1.5× 18 0.2× 130 1.9× 123 2.0× 5 339
Janice M. Mehnert United States 8 303 2.2× 40 0.4× 58 0.7× 183 2.7× 52 0.9× 24 409

Countries citing papers authored by Steffen Falgreen

Since Specialization
Citations

This map shows the geographic impact of Steffen Falgreen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Falgreen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Falgreen more than expected).

Fields of papers citing papers by Steffen Falgreen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Falgreen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Falgreen. The network helps show where Steffen Falgreen may publish in the future.

Co-authorship network of co-authors of Steffen Falgreen

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Falgreen. A scholar is included among the top collaborators of Steffen Falgreen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Falgreen. Steffen Falgreen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Laursen, Maria Bach, Anna A. Schönherz, Rasmus Røge, et al.. (2019). High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients. Oncotarget. 10(7). 717–731. 20 indexed citations
2.
Bødker, Julie Støve, Marianne Tang Severinsen, Tarec Christoffer El‐Galaly, et al.. (2017). Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission. Experimental Hematology and Oncology. 6(1). 3–3. 1 indexed citations
3.
Laursen, Maria Bach, Steffen Falgreen, Anders Ellern Bilgrau, et al.. (2016). High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Experimental Hematology. 44(4). 238–246.e2. 55 indexed citations
4.
Bilgrau, Anders Ellern, Steffen Falgreen, Malene Krag Kjeldsen, et al.. (2016). Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates. BMC Bioinformatics. 17(1). 159–159. 4 indexed citations
5.
Falgreen, Steffen, Anders Ellern Bilgrau, Rasmus Froberg Brøndum, et al.. (2016). hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. PLoS ONE. 11(10). e0163711–e0163711. 6 indexed citations
6.
Jensen, Andreas Kryger, René Holst, Steffen Falgreen, et al.. (2016). Multiplex polymerase chain reaction‐based prognostic models in diffuse large B‐cell lymphoma patients treated with R‐CHOP. British Journal of Haematology. 174(6). 876–886. 7 indexed citations
7.
Sørensen, Suzette, Steffen Falgreen, Julie Støve Bødker, et al.. (2016). Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review.. PubMed. 63(3). 2 indexed citations
8.
Falgreen, Steffen, Karen Dybkær, Ken H. Young, et al.. (2015). Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer. 15(1). 235–235. 35 indexed citations
9.
Laursen, Maria Bach, Steffen Falgreen, Alexander Schmitz, et al.. (2015). High Expression of CXCR4 Impairs Anti-CD20 Monoclonal Antibody (Rituximab)-Dependent Cytotoxicity in Diffuse Large B-Cell Lymphoma. Blood. 126(23). 1455–1455. 2 indexed citations
10.
Falgreen, Steffen, Maria Bach Laursen, Julie Støve Bødker, et al.. (2014). Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. BMC Bioinformatics. 15(1). 168–168. 14 indexed citations
11.
Laursen, Maria Bach, Steffen Falgreen, Julie Støve Bødker, et al.. (2014). Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Experimental Hematology. 42(11). 927–938. 12 indexed citations
12.
Laursen, Maria Bach, Julie Støve Bødker, Malene Krag Kjeldsen, et al.. (2014). MicroRNAs in B-cells: from normal differentiation to treatment of malignancies. Oncotarget. 6(1). 7–25. 22 indexed citations
13.
Nyegaard, Mette, Martin Bøgsted, Alexander Schmitz, et al.. (2014). Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunology. 15(1). 3–3. 9 indexed citations
14.
Bilgrau, Anders Ellern, Alexander Schmitz, Steffen Falgreen, et al.. (2014). Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. Cytometry Part B Clinical Cytometry. 88(1). 40–49. 23 indexed citations
15.
Bilgrau, Anders Ellern, Alexander Schmitz, Steffen Falgreen, et al.. (2014). Stable Phenotype Of B-Cell Subsets Following Cryopreservation and Thawing of Normal Human Lymphocytes Stored in a Tissue Biobank. Cytometry Part B Clinical Cytometry. n/a–n/a. 19 indexed citations
16.
Johnsen, Hans Erik, Julie Støve Bødker, Alexander Schmitz, et al.. (2014). A Multiple Myeloma Classification System That Associates Normal Bone Marrow B-Cell Subset Phenotypes with Disease Stage and Prognosis. Blood. 124(21). 3352–3352. 2 indexed citations
17.
Rodrigo-Domingo, María, Rasmus Waagepetersen, Julie Støve Bødker, et al.. (2013). Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Briefings in Bioinformatics. 15(4). 519–533. 9 indexed citations
18.
Bilgrau, Anders Ellern, María Rodrigo-Domingo, Alexander Schmitz, et al.. (2012). A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells. BMC Genomics. 13(1). 596–596. 1 indexed citations
19.
Falgreen, Steffen, Suzette Sørensen, Alexander Schmitz, et al.. (2011). Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines. PLoS ONE. 6(4). e19322–e19322. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey C. Xing Breakdown of academic impact, for papers by Stéphanie Sungalee Breakdown of academic impact, for papers by Rina Kurisu Breakdown of academic impact, for papers by Luke B. Fletcher Breakdown of academic impact, for papers by Elena Battistello Breakdown of academic impact, for papers by Jens Wuerthner Breakdown of academic impact, for papers by Romina Royo Breakdown of academic impact, for papers by Martina Fröhlich Breakdown of academic impact, for papers by Elizabeth Carideo Breakdown of academic impact, for papers by Janice M. Mehnert
Rankless by CCL
2026